AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 95 filers reported holding AKERO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,184,804 | -7.6% | 43,195 | -14.7% | 0.00% | 0.0% |
| Q2 2023 | $2,363,402 | +120.0% | 50,619 | +80.3% | 0.00% | +100.0% |
| Q1 2023 | $1,074,379 | -26.4% | 28,081 | +5.4% | 0.00% | -50.0% |
| Q4 2022 | $1,459,817 | +231.0% | 26,639 | +105.3% | 0.00% | – |
| Q3 2022 | $441,000 | +261.5% | 12,976 | +1.2% | 0.00% | – |
| Q2 2022 | $122,000 | -23.3% | 12,827 | +14.8% | 0.00% | – |
| Q1 2022 | $159,000 | -30.6% | 11,178 | +3.1% | 0.00% | – |
| Q4 2021 | $229,000 | -66.4% | 10,838 | -64.5% | 0.00% | – |
| Q3 2021 | $682,000 | +166.4% | 30,572 | +195.8% | 0.00% | – |
| Q2 2021 | $256,000 | -21.5% | 10,337 | -7.8% | 0.00% | – |
| Q1 2021 | $326,000 | -55.6% | 11,215 | -60.7% | 0.00% | – |
| Q4 2020 | $735,000 | +141.8% | 28,503 | +188.5% | 0.00% | – |
| Q3 2020 | $304,000 | – | 9,879 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |